Honeywell International Inc. (HON) Reaches $147.39 52-Week High; Idera Pharmaceuticals (IDRA) SI Decreased By 64.47%

November 14, 2017 - By Michael Collier

The stock of Honeywell International Inc. (NYSE:HON) hit a new 52-week high and has $153.29 target or 4.00% above today’s $147.39 share price. The 9 months bullish chart indicates low risk for the $112.29 billion company. The 1-year high was reported on Nov, 14 by Barchart.com. If the $153.29 price target is reached, the company will be worth $4.49B more. About 1.64M shares traded. Honeywell International Inc. (NYSE:HON) has risen 17.66% since November 14, 2016 and is uptrending. It has outperformed by 0.96% the S&P500.

Idera Pharmaceuticals Incorporated (NASDAQ:IDRA) had a decrease of 64.47% in short interest. IDRA’s SI was 3.06 million shares in November as released by FINRA. Its down 64.47% from 8.61 million shares previously. With 4.26M avg volume, 1 days are for Idera Pharmaceuticals Incorporated (NASDAQ:IDRA)’s short sellers to cover IDRA’s short positions. The SI to Idera Pharmaceuticals Incorporated’s float is 2.23%. About 1.94M shares traded. Idera Pharmaceuticals Inc (NASDAQ:IDRA) has risen 21.13% since November 14, 2016 and is uptrending. It has outperformed by 4.43% the S&P500.

Honeywell International Inc. is a technology and manufacturing company. The company has market cap of $112.29 billion. The Firm operates through four divisions: Aerospace, Home and Building Technologies, Performance Materials and Technologies, and Safety and Productivity Solutions. It has a 22.34 P/E ratio. The Company’s Aerospace segment supplies products, software and services for aircraft and vehicles that it sells to original equipment manufacturers and other customers.

Investors sentiment decreased to 0.96 in Q2 2017. Its down 0.08, from 1.04 in 2017Q1. It is negative, as 58 investors sold Honeywell International Inc. shares while 492 reduced holdings. 104 funds opened positions while 426 raised stakes. 562.97 million shares or 0.95% less from 568.40 million shares in 2017Q1 were reported. Hsbc Public Ltd Com reported 0.34% stake. Jolley Asset Management Limited Company invested in 0.07% or 775 shares. Tradewinds Management Limited Liability Co holds 13,152 shares or 0.92% of its portfolio. Loeb Partners Corp invested in 11,600 shares or 0.44% of the stock. San Francisco Sentry Grp Inc (Ca) holds 1.4% of its portfolio in Honeywell International Inc. (NYSE:HON) for 29,411 shares. Asset Mgmt holds 0.34% in Honeywell International Inc. (NYSE:HON) or 14,256 shares. Massachusetts-based Acadian Asset Ltd Liability Com has invested 0.02% in Honeywell International Inc. (NYSE:HON). Raymond James & Assocs holds 942,502 shares. Koshinski Asset Management stated it has 5,063 shares or 0% of all its holdings. Alabama-based Cabot has invested 0.21% in Honeywell International Inc. (NYSE:HON). Hyman Charles D owns 28,062 shares. Adage Capital Prtnrs Group Inc Ltd Liability Co reported 2.28M shares. Lumbard & Kellner invested in 0.41% or 5,408 shares. Stellar Capital Limited Liability Com holds 0.27% or 2,735 shares. Baker Ellis Asset Management Ltd owns 0.74% invested in Honeywell International Inc. (NYSE:HON) for 20,181 shares.

Among 21 analysts covering Honeywell International Inc. (NYSE:HON), 17 have Buy rating, 0 Sell and 4 Hold. Therefore 81% are positive. Honeywell International Inc. has $170 highest and $7 lowest target. $132.66’s average target is -9.99% below currents $147.39 stock price. Honeywell International Inc. had 76 analyst reports since July 30, 2015 according to SRatingsIntel. Morgan Stanley maintained the stock with “Overweight” rating in Friday, September 22 report. The firm earned “Overweight” rating on Monday, October 5 by Barclays Capital. The stock of Honeywell International Inc. (NYSE:HON) has “Buy” rating given on Tuesday, July 21 by Argus Research. As per Sunday, October 22, the company rating was maintained by RBC Capital Markets. The stock has “Buy” rating by Oppenheimer on Tuesday, August 8. The firm has “Buy” rating given on Friday, May 26 by Jefferies. The stock of Honeywell International Inc. (NYSE:HON) has “Hold” rating given on Monday, October 23 by Credit Suisse. On Friday, May 26 the stock rating was maintained by RBC Capital Markets with “Buy”. Morgan Stanley maintained it with “Overweight” rating and $145 target in Wednesday, August 16 report. The stock of Honeywell International Inc. (NYSE:HON) has “Outperform” rating given on Monday, October 19 by RBC Capital Markets.

Analysts await Honeywell International Inc. (NYSE:HON) to report earnings on January, 26. They expect $1.85 earnings per share, up 6.32% or $0.11 from last year’s $1.74 per share. HON’s profit will be $1.41 billion for 19.92 P/E if the $1.85 EPS becomes a reality. After $1.75 actual earnings per share reported by Honeywell International Inc. for the previous quarter, Wall Street now forecasts 5.71% EPS growth.

Since May 19, 2017, it had 0 insider purchases, and 3 sales for $16.46 million activity. Another trade for 3,430 shares valued at $451,765 was made by SHEARES BRADLEY T on Friday, May 19. 116,021 shares were sold by Adams Katherine L., worth $15.28 million. $726,659 worth of Honeywell International Inc. (NYSE:HON) shares were sold by Mak Jennifer H.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The company has market cap of $407.28 million. The Firm utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor targeting technology and third-generation antisense (3GA) technology. It currently has negative earnings. Using TLR technology, the Company creates synthetic oligonucleotide drug candidates to act by modulating the activity of specific TLRs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com